PMID- 21278072
OWN - NLM
STAT- MEDLINE
DCOM- 20111123
LR  - 20220409
IS  - 1462-0332 (Electronic)
IS  - 1462-0324 (Linking)
VI  - 50
IP  - 6
DP  - 2011 Jun
TI  - Rituximab infusion-related adverse event rates are lower in patients with 
      systemic lupus erythematosus than in those with rheumatoid arthritis.
PG  - 1148-52
LID - 10.1093/rheumatology/keq436 [doi]
AB  - OBJECTIVES: Rituximab (RTX) is a therapeutic option for patients with SLE or RA. 
      We conducted a prospective, longitudinal, observational study to compare rates of 
      RTX-related adverse events (AEs) in these two patient groups. METHODS: RTX was 
      used in 23 patients with SLE that was refractory to conventional therapy and in 
      31 patients with RA that had been unsuccessfully treated with TNF-alpha inhibitors. 
      Infusion-related and infectious AE rates were calculated for each group. RESULTS: 
      Seven (22.5%) RA patients experienced an infusion-related reaction. These AEs 
      involved 7/91 (7.7%) infusions administered in the RA group. None of the 102 
      infusions administered to SLE patients was associated with infusion-related AEs 
      (P = 0.038 vs RA group). The mean daily glucocorticoid dose administered during 
      the week preceding RTX treatment in the SLE group was higher than that for the RA 
      group [0.25 (0.2) vs 0.18 (0.14) mg/kg, P = not significant] and significantly 
      higher than that received by the subgroup of the seven RA patients who 
      experienced infusion-related AEs [0.10 (0.02) mg/kg; P = 0.0017]. Infectious AE 
      rates were also lower (but not significantly so) in the SLE group (8.7 vs 12.9% 
      in RA). CONCLUSIONS: Repeated cycles of RTX in combination with different 
      immunosuppressants is a safe therapeutic option for SLE and RA patients. The 
      lower incidence of infusion-related AEs in the SLE patients might reflect the 
      higher dosage glucocorticoid therapy they received during the week before RTX 
      infusion.
FAU - Conti, Fabrizio
AU  - Conti F
AD  - Dipartimento di Medicina Interna e Specialita Mediche, Reumatologia, Sapienza 
      Universita di Roma, Rome, Italy.
FAU - Ceccarelli, Fulvia
AU  - Ceccarelli F
FAU - Perricone, Carlo
AU  - Perricone C
FAU - Alessandri, Cristiano
AU  - Alessandri C
FAU - Conti, Virginia
AU  - Conti V
FAU - Massaro, Laura
AU  - Massaro L
FAU - Truglia, Simona
AU  - Truglia S
FAU - Spinelli, Francesca R
AU  - Spinelli FR
FAU - Spadaro, Antonio
AU  - Spadaro A
FAU - Valesini, Guido
AU  - Valesini G
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20110128
PL  - England
TA  - Rheumatology (Oxford)
JT  - Rheumatology (Oxford, England)
JID - 100883501
RN  - 0 (Antibodies, Monoclonal, Murine-Derived)
RN  - 0 (Antirheumatic Agents)
RN  - 4F4X42SYQ6 (Rituximab)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antibodies, Monoclonal, Murine-Derived/*adverse effects/therapeutic use
MH  - Antirheumatic Agents/*adverse effects/therapeutic use
MH  - Arthritis, Rheumatoid/diagnosis/*drug therapy
MH  - Cohort Studies
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Drug-Related Side Effects and Adverse Reactions/*epidemiology/etiology
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Incidence
MH  - Infusions, Intravenous
MH  - Lupus Erythematosus, Systemic/diagnosis/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Risk Assessment
MH  - Rituximab
MH  - Safety Management
MH  - Severity of Illness Index
MH  - Statistics, Nonparametric
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2011/02/01 06:00
MHDA- 2011/12/13 00:00
CRDT- 2011/02/01 06:00
PHST- 2011/02/01 06:00 [entrez]
PHST- 2011/02/01 06:00 [pubmed]
PHST- 2011/12/13 00:00 [medline]
AID - keq436 [pii]
AID - 10.1093/rheumatology/keq436 [doi]
PST - ppublish
SO  - Rheumatology (Oxford). 2011 Jun;50(6):1148-52. doi: 10.1093/rheumatology/keq436. 
      Epub 2011 Jan 28.